The overall goal of this project is to develop new bifunctional chelating agents (BCAs) for the radiolabeling of monoclonal antibodies (MAbs) with radiometals other than 90Y for radioimmunotherapy in animal studies and ultimately clinically. We are proposing to study in this application a novel family of BCAs for radiolabeling of MAb CC49. The MAb CC49 is a well characterized reagent reactive with human adenocarcinomas and is being used in clinical phase and phase Il localization and therapy trials by us and other investigators. Therefore, the animal studies proposed in this application will elucidate the therapeutic efficacy, stability and other characteristics of BCA radiometal labeled conjugates, with the long term goal of their use in human clinical therapy trials.
The specific aims are 1) To optimize the ability of trisuccin, a new hydroxamic acid based BCA to bind various radioactive metals to monoclonal antibodies for radioimmunoimaging and radioimmunotherapy, 2) To expand this """"""""family"""""""" of hydroxamic acid-based BCAs to provide alternative or improved radioisotope linking strategies, 3) To radiolabel the MAb CC49 with 99mTc, 186Re and 67Cu using trisuccin and other hydroxamic acid-based BCAs, 4) To characterize the immunoreactivity, the in vitro and in vivo stability of hydroxamic acid chelated monoclonal antibodies labeled with the above radioisotopes. 5) To compare the tumor localization and biodistribution of radioisotopes linked to MAb CC49 via hydroxamic acid BCAs versus 99mTc and 186Re-MAG2-GABA-labeled CC49, and 6) To compare radioimmunotherapy effects of radiolabeled CC49 when radioisotopes are linked by hydroxamic acid based BCAs versus 99mTc and 186Re-MAG2-GABA- labeled CC49. Standard analytical and biochemical techniques will be used to demonstrate the purity of the hydroxamic acid compounds synthesized. Stability and pharmacokinetic studies will be carried out in rabbits. The biodistribution and therapy studies will be carried out in athymic nude mice bearing subcutaneous human colon cancer xenografts. The eventual goal of this project is to produce a better radioimmunotherapeutic agent for treatment of human malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA062550-03
Application #
2633869
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Mahoney, Francis J
Project Start
1996-02-01
Project End
1999-05-31
Budget Start
1998-01-01
Budget End
1999-05-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Safavy, Ahmad; Smith Jr, Dale C; Bazooband, Alireza et al. (2002) Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent. Bioconjug Chem 13:327-32
Safavy, Ahmad; Smith Jr, Dale C; Bazooband, Alireza et al. (2002) De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent. Bioconjug Chem 13:317-26
Buchsbaum, D J; Curiel, D T (2001) Gene therapy for the treatment of cancer. Cancer Biother Radiopharm 16:275-88
Buchsbaum, D J (2000) Experimental radioimmunotherapy. Semin Radiat Oncol 10:156-67
Safavy, A; Khazaeli, M B; Kirk, M et al. (1999) Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci. Bioconjug Chem 10:18-23
Safavy, A; Khazaeli, M B; Safavy, K et al. (1999) Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Clin Cancer Res 5:2994s-3000s
Buchsbaum, D J; Rogers, B E; Khazaeli, M B et al. (1999) Targeting strategies for cancer radiotherapy. Clin Cancer Res 5:3048s-3055s
Safavy, A; Sanders, A; Qin, H et al. (1997) Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol. Bioconjug Chem 8:766-71
Safavy, A; Khazaeli, M B; Qin, H et al. (1997) Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer 80:2354-9
Buchsbaum, D J (1997) Experimental tumor targeting with radiolabeled ligands. Cancer 80:2371-7